Related Experiment Videos
Expression of 65-kDa oncofetal protein in experimental hepatoma after anticancer therapy
M Mirowski1, M Rozalski, U Krajewska
1Department of Biochemistry, Medical University, Lodz, Poland.
Abstract:
We have tested the expression of a 65-kDa oncofetal protein (p65) after combined treatment with menadione and methotrexate in hamsters transplanted with Kirkman-Robins hepatoma. The treatment of tumor-bearing animals with these compounds significantly inhibited both the tumor development and the expression of p65. This inhibition in tumor tissue was calculated from densitograms of Western blots. The inhibition of p65 expression was also confirmed in the serum of hepatoma bearing animals by using solid-phase radioimmunoassay (RIA) to quantify the specificity of polyclonal antibodies to fetal p65 molecules. Additionally, p65 was shown to localize both in cytoplasm and in the nuclear extracts prepared from hepatoma tissue.
Insights
Combined treatment with menadione and methotrexate inhibited hepatoma development and oncofetal protein p65 expression in hamsters. This reduction in p65 was observed in both tumor tissue and serum, indicating a significant therapeutic effect.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Oncofetal proteins like p65 are potential biomarkers in cancer.
- Hepatoma is a significant health concern requiring effective treatment strategies.
Purpose of the Study:
- To investigate the effect of combined menadione and methotrexate treatment on hepatoma tumor development.
- To assess the impact of this combined treatment on the expression of the 65-kDa oncofetal protein (p65).
Main Methods:
- Treatment of hamsters bearing Kirkman-Robins hepatoma with menadione and methotrexate.
- Quantification of p65 expression in tumor tissue using Western blot densitometry.
- Measurement of serum p65 levels via solid-phase radioimmunoassay (RIA).
Main Results:
- Combined treatment significantly inhibited hepatoma tumor growth.
- A notable decrease in p65 expression was observed in tumor tissue.
- Serum p65 levels were also reduced, confirming the inhibition of p65 expression.
- p65 was localized in both the cytoplasm and nuclear extracts of hepatoma tissue.
Conclusions:
- Combined menadione and methotrexate therapy is effective in inhibiting hepatoma development.
- This treatment regimen downregulates the expression of the oncofetal protein p65.
- p65 may serve as a relevant biomarker for monitoring treatment response in hepatoma.